The TNBC market is expanding rapidly due to increasing incidence and advancements in targeted therapies. Key players including Merck (Keytruda), Gilead (Trodelvy), and AstraZeneca are driving innovation with novel antibody-drug conjugates and immunotherapies that improve survival rates. Biomarker development and combination regimens are creating more effective treatment approaches for this aggressive cancer subtype.
Access Market Report: https://shorturl.at/ruuiQ
Мне нравится
Комментарий
Перепост
